Recurrent Head and Neck Squamous Cell Carcinoma Clinical Trials in Chicago, Illinois

3 studies are recruiting for recurrent head and neck squamous cell carcinoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

    This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first started (primary s…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Chicago Comprehensive Cancer Center, Chicago, Illinois
    Locations
    199 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT06589804 on ClinicalTrials.gov

  2. Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

    This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head …

    Stage
    Phase 2
    Ages
    18 to 79
    Site
    Northwestern University, Chicago, Illinois
    Locations
    178 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT04671667 on ClinicalTrials.gov

  3. A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

    The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cet…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Illinois Cancer Center, Chicago, Illinois
    Locations
    112 in total
    Run by
    AVEO Pharmaceuticals, Inc.

    See if you can join NCT06064877 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.